Longeveron Inc. Q3 2025 Earnings Recap

LGVN Q3 2025 November 5, 2025

Get alerts when LGVN reports next quarter

Longeveron reported significant advancements in Q3 2025, including the completion of enrollment in its pivotal HLHS clinical trial and a focused strategy to secure additional financing.

Earnings Per Share Beat

$-0.39 vs $-2.60 est.

+85.0% surprise

Revenue Miss

137000 vs 266000 est.

-48.5% surprise

Market Reaction

Nov 5 to Nov 12 -7.09%

Nov 5 to Dec 8 -22.18%

See LGVN alongside your other holdings

Add to your portfolio — free

Key Takeaways

Completed enrollment for the ELPIS II pivotal Phase IIb clinical trial, with results expected in Q3 2026, paving the way for potential regulatory approval.
Extended cash runway into late Q1 2026 through operational decisions and an at-the-market financing facility, with potential to raise up to $10.7 million if needed.
Focus on bolstering BLA preparedness ahead of the ELPIS II data release, with adjusted timelines for full BLA filing anticipated in 2027.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit LGVN on AllInvestView.